# A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

> **NCT00551252** · PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano MEsotelioma** · enrollment: 56 (estimated)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Imatinib mesylate plus Gemcitabine

## Key facts

- **NCT ID:** NCT00551252
- **Lead sponsor:** Gruppo Italiano MEsotelioma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-01
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2007-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551252, "A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00551252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*